Department of Medicine, University of California, Los Angeles, CA, USA.
Am J Transplant. 2009 Dec;9(12):2851-4. doi: 10.1111/j.1600-6143.2009.02860.x.
Hepatocellular carcinoma (HCC) remains a significant disease worldwide and its incidence is expected to increase. In selected patients, liver transplantation offers a 5-year patient survival between 48% and 75%. However, HCC recurrence occurs in approximately 20% of transplant recipients. No therapy has proven efficacious in decreasing the risk of recurrence after transplantation. Sorafenib, a multitargeted tyrosine kinase inhibitor, has been shown to improve survival in patients with advanced HCC that have no history of liver transplantation. We report complete remission of HCC in a 54-year-old man who developed biopsy-proven lung metastasis after liver transplantation treated with sorafenib.
肝细胞癌 (HCC) 仍然是全球范围内的一种重要疾病，其发病率预计将会增加。在某些特定患者中，肝移植的 5 年患者生存率在 48%至 75%之间。然而，约 20%的移植受者会出现 HCC 复发。在肝移植后，尚无任何疗法能够有效降低复发风险。索拉非尼是一种多靶点酪氨酸激酶抑制剂，已被证明可改善无肝移植史的晚期 HCC 患者的生存。我们报告了一例 54 岁男性的 HCC 完全缓解病例，该患者在肝移植后发生了经活检证实的肺转移，接受索拉非尼治疗后病情得到缓解。
